Septerna, Inc. $SEPN Shares Acquired by Driehaus Capital Management LLC

Key Points

• Driehaus Capital Management LLC increased its stake in Septerna, Inc. (NASDAQ: SEPN) by 20.6%, owning approximately 7.01% of the company with an investment worth $18.08 million.
• Several institutional investors have made significant investments in Septerna, including TRV GP VI LLC, which boosted its stake by 33.6%, now holding shares worth $24.39 million.
• Despite a market cap of $539.42 million, Septerna reported a net margin of -12,053.03% and earnings significantly below expectations, with a recent earnings per share (EPS) of ($0.56).

Driehaus Capital Management LLC boosted its position in Septerna, Inc. (NASDAQ:SEPN - Free Report) by 20.6% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,122,608 shares of the company's stock after purchasing an additional 533,055 shares during the quarter. Driehaus Capital Management LLC owned approximately 7.01% of Septerna worth $18,080,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Tower Research Capital LLC TRC bought a new position in Septerna in the fourth quarter worth about $25,000. Legal & General Group Plc acquired a new position in shares of Septerna during the fourth quarter valued at about $42,000. BNP Paribas Financial Markets acquired a new position in shares of Septerna during the fourth quarter valued at about $52,000. Rhumbline Advisers increased its holdings in shares of Septerna by 16.6% during the first quarter. Rhumbline Advisers now owns 23,318 shares of the company's stock valued at $135,000 after acquiring an additional 3,323 shares in the last quarter. Finally, Deutsche Bank AG increased its holdings in shares of Septerna by 53.3% during the first quarter. Deutsche Bank AG now owns 15,968 shares of the company's stock valued at $92,000 after acquiring an additional 5,549 shares in the last quarter.

Septerna Price Performance

NASDAQ SEPN traded down $0.18 during mid-day trading on Monday, hitting $12.10. The stock had a trading volume of 197,661 shares, compared to its average volume of 230,640. The firm's 50 day moving average is $11.86 and its 200 day moving average is $8.98. Septerna, Inc. has a twelve month low of $4.17 and a twelve month high of $28.99. The stock has a market capitalization of $539.42 million and a price-to-earnings ratio of -1.20.

Septerna (NASDAQ:SEPN - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.51). Septerna had a negative net margin of 12,053.03% and a negative return on equity of 31.52%. The firm had revenue of $0.12 million during the quarter, compared to analyst estimates of $22.50 million. As a group, equities research analysts expect that Septerna, Inc. will post -7.11 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Cantor Fitzgerald upped their price objective on shares of Septerna from $20.00 to $25.00 and gave the company an "overweight" rating in a report on Friday, May 16th. HC Wainwright restated a "buy" rating and set a $26.00 price objective on shares of Septerna in a report on Thursday, August 21st. Wall Street Zen downgraded shares of Septerna from a "hold" rating to a "sell" rating in a report on Saturday, August 16th. Finally, Wells Fargo & Company upped their price objective on shares of Septerna from $11.00 to $18.00 and gave the company an "equal weight" rating in a report on Friday, May 16th. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $26.75.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.